BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Study of BioAegis’ Lead Product, Gelsolin, is Key Component of NIAID Strategic Plan for COVID-19 Research
May 21, 2020 13:58 ET | BioAegis Therapeutics
MORRISTOWN, N.J., May 21, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announces that the National Institute of Health (NIH) Clinical Center is measuring patient gelsolin levels as part of...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Demonstrates Gelsolin Therapy Can Quell the Cytokine Storm and Promote Tissue Repair
April 27, 2020 01:15 ET | BioAegis Therapeutics
MORRISTOWN, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. has highlighted recently published gene expression data in animal studies where recombinant human plasma gelsolin...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Small NJ Biotech Firm, BioAegis Therapeutics, Accelerating Multiple Clinical Trial Submissions for Severe COVID-19 Pneumonia Patients
April 02, 2020 02:15 ET | BioAegis Therapeutics
MORRISTOWN, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. is a clinical stage, private company focused on developing therapies for infectious, inflammatory, and degenerative...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces Publication: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza"
December 12, 2019 09:05 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical stage company developing technology to address injurious inflammation while protecting immune function and...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Named New Jersey’s Most Valuable Venture-Backed Company Led by a Woman
October 22, 2019 16:53 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Oct. 22, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics was recently recognized by PitchBook as the most valuable venture-backed company in New Jersey led by a female entrepreneur....
Survival at Day 10
BioAegis Therapeutics Announces Publication in the Journal of Infectious Diseases: "Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Penicillin-Sensitive and Resistant Pneumococcal Pneumonia"
August 22, 2019 10:15 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 22, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc., a clinical-stage company developing technology to control inflammation while protecting immune function and vital...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Reports Favorable Safety and Pharmacokinetic Results in its Phase 1b/2a Dose-Escalation Study of Recombinant Human Plasma Gelsolin with Highest Doses Ever Administered to Patients
August 07, 2019 10:00 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, Inc. announced the major findings from its Phase 1b/2a study of Recombinant Human Plasma Gelsolin for patients requiring...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Completes Enrollment in its Phase 1b/2a Dose-Ranging Safety Study of Recombinant Plasma Gelsolin for Community-Acquired Pneumonia
March 18, 2019 11:00 ET | BioAegis Therapeutics
MORRISTOWN, N.J., March 18, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that it has completed patient enrollment in its Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN)...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Expands Phase 1b/2a Community-Acquired Pneumonia Study to the Republic of Georgia —Successfully Completes Second of Four Dosing Cohorts
February 07, 2019 09:17 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 07, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced that patient enrollment is underway in a Phase 1b/2a study of recombinant plasma gelsolin (rhu-pGSN) in...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Announces Publication in “Clinical Infectious Diseases” Linking Depleted Plasma Gelsolin Concentrations at Admission to Severe Pneumonia Outcomes in CDC-Sponsored “Etiology of Pneumonia in the Community (EPIC)” Study
February 01, 2019 10:53 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 01, 2019 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc. announced the publication of a paper in Clinical Infectious Disease—a journal of the Infectious Disease Society of...